Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | BAD | Q92934 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SPR | P35270 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19679237 | 0.96 | BCL2L1 (0.47) | BCL2L1BADALDH1A1HSD17B10TSHR | |
| SCHEMBL30305680 | 0.82 | BCL2L1 (0.45) | BCL2L1BADALDH1A1MEN1KMT2A | |
| SCHEMBL2264771 | 0.78 | AR (0.37) | HPGDMAPTKDM4EGAAPARP1 | |
| SCHEMBL3675894 | 0.77 | BCL2L1 (0.50) | BCL2L1BADALDH1A1HPGDMEN1 | |
| SCHEMBL15129334 | 0.77 | ADRA2A (0.40) | ALDH1A1HSD17B10TSHRHPGDMEN1 | |
| SCHEMBL31741019 | 0.77 | ADRA2A (0.40) | ALDH1A1HSD17B10TSHRHPGDMEN1 | |
| SCHEMBL156631 | 0.76 | MEN1 (0.37) | MEN1KMT2AMAPTPARP1DRD2 | |
| SCHEMBL8436954 | 0.74 | BCL2L1 (0.42) | BCL2L1BADALDH1A1MEN1KMT2A | |
| SCHEMBL22618626 | 0.74 | BCL2L1 (0.42) | BCL2L1BADALDH1A1MEN1KMT2A | |
| SCHEMBL22618624 | 0.74 | BCL2L1 (0.42) | BCL2L1BADALDH1A1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728155-B2 | Dihydrobenzofuranyl alkanamines and methods for using same as cns agents | WYETH LLC (US) | 2010-06-01 | — | — | US | disclosed |
| CN-100448861-C | Dihydrobenzofuranyl alkanamines and pharmaceutical compositions containing them | WYETH CORP (US) | 2009-01-07 | — | — | CN | disclosed |
| CN-1871226-A | Dihydrobenzofuranalkylamines and pharmaceutical compositions containing them | WYETH CORP (US) | 2006-11-29 | — | — | CN | disclosed |
| EP-1675842-A1 | DIHYDROBENZOFURANYL ALKANAMINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Wyeth (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20050124692-A1 | Dihydrobenzofuranyl alkanamines and methods for using same as cns agents | WYETH (US) | 2005-06-09 | — | — | US | disclosed |
| WO-2005040146-A1 | DIHYDROBENZOFURANYL ALKANAMINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | WYETH (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124692-A1 | Dihydrobenzofuranyl alkanamines and methods for using same as cns agents | HTR2C, HTR1A, HTR1B | BCL2L1 2673/4885BAD 781/4885ALDH1A1 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.